BY PETER LOFTUS
Johnson & Johnson doesn't expect to receive new supplies of its cancer drug Doxil from a troubled contract manufacturer's plant until late 2012, at the earliest.
J&J will pursue other options to bring Doxil back to patients, including shifting production to another supplier, spokeswoman Lisa Vaga said Friday.
Problems at J&J's sole supplier for Doxil, Ben Venue Laboratories Inc., caused a shortage of the drug beginning about six months ago. J&J and Ben Venue have managed to squeeze out periodic batches to patients since then, but about 1,000 remain on a waiting list to receive Doxil, which treats ovarian and ...
BY PETER LOFTUS
Johnson & Johnson doesn't expect to receive new supplies of its cancer drug Doxil from a troubled contract manufacturer's plant until late 2012, at the earliest.
J&J will pursue other options to bring Doxil back to patients, including shifting production to another supplier, spokeswoman Lisa Vaga said Friday.
Problems at J&J's sole supplier for Doxil, Ben Venue Laboratories Inc., caused a shortage of the drug beginning about six months ago. J&J and Ben Venue have managed to squeeze out periodic batches to patients since then, but about 1,000 remain on a waiting list to receive Doxil, which treats ovarian and ...
fsu football do a barrelroll bérénice marlohe bérénice marlohe google offers tim gunn tim gunn
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.